Dual-target CAR-T cells for relapsed or refractory AML
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have acute myeloid leukemia (not a type called APL) that has come back or not gotten better with treatment.
- Your leukemia cells have the CLL1 or CD38 protein (or both).
- You have a donor ready for a stem cell transplant, and you could have that transplant after getting the study treatment.
- You are not taking high doses of steroids or other strong immune-suppressing drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new kind of immunotherapy called CAR-T cells that are engineered to find and attack leukemia cells carrying certain markers (CD33, CD123, or CLL-1). The treatment is given in two steps, aiming to kill cancer cells more effectively and possibly with fewer side effects.
This study tests a new treatment using your own immune cells, modified to find and kill leukemia cells that have a marker called CLL1. It is for people with AML that has come back or not responded to standard care, and it may be followed by a stem cell transplant.
This study tests a universal CAR-T cell therapy for acute myeloid leukemia (AML), a type of blood cancer. The treatment uses specially engineered immune cells to target leukemia cells with certain markers, and the trial aims to see if it is safe and effective for patients whose leukemia has not responded to standard treatments.
This trial tests a new type of cell therapy called NKG2D CAR-T for people with AML that has not responded to standard treatment or has come back. It aims to use your own immune cells, modified to attack the leukemia, to help you achieve remission.
This trial tests a new treatment using your donor's immune cells that are engineered to find and attack cancer cells with a specific marker called CD117. It's for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments.
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.